The direct answer
Neither NMN nor NR is the proven universal winner. In a 2026 randomized four-arm trial, 15 participants assigned to NMN and 16 assigned to NR took 1,000 mg/day for 14 days. Both groups roughly doubled whole-blood NAD+ from baseline, and the researchers described the increases as comparable. The trial measured circulating NAD metabolism, not energy, longevity, disease prevention, or a difference in clinical benefit.
That shifts the practical decision from “Which acronym wins?” to “Which actual product has the dose, price, finished-product documentation, and formula you want?” A well-documented NR bottle can be a stronger purchase than a poorly documented NMN bottle, and the reverse is also true.
The 2026 head-to-head trial
One study now compares the two precursors directly, but its endpoint and duration remain narrow.
| Trial field | NMN | NR | What the result means |
|---|---|---|---|
| Analyzed groupModified intention-to-treat | 15 participants | 16 participants | Small groups in one short trial. |
| Dose and duration | 1,000 mg/day for 14 days | 1,000 mg/day for 14 days | An equal-dose comparison, not a dose-ranging test. |
| Whole-blood NAD+Difference from placebo | 43.1 µM; 95% CI 32.7–53.4 | 49.4 µM; 95% CI 39.5–59.3 | Both increased NAD+; the study characterized them as comparable. |
| Clinical outcome | Not established | Not established | The result does not prove better symptoms, health span, or longevity. |
What is chemically different
NR is a nucleoside. NMN is a nucleotide that includes a phosphate group. Both sit within the network of compounds the body uses to make and recycle NAD+. That biochemical distinction does not by itself tell a shopper which oral supplement will produce a better clinical result. Human absorption, metabolism, dose, formulation, and the outcome being measured all matter.
The direct trial also found that both precursors changed circulating metabolites beyond NAD+ itself. That is useful mechanistic evidence, but it remains different from showing that one product improves a patient-important outcome.
How the broader human evidence compares
- NMN
- Trials have tested 250 to 2,000 mg/day across different populations and durations. Blood NAD-related measures often rise, while effects on metabolic and physical outcomes are inconsistent.
- NR
- Trials including 1,000 mg/day for six weeks and 100 to 1,000 mg/day for eight weeks have reported increases in blood NAD-related measures. Clinical benefits are not established across users.
- Shared result
- Both compounds can raise circulating NAD-related measures under studied conditions.
- Shared uncertainty
- Neither has been shown to extend human lifespan, and biomarker changes do not establish a felt or durable health benefit.
Separate trials cannot be treated as a clean race. They use different populations, doses, durations, assays, comparators, and endpoints. The 2026 direct study is more informative for relative NAD+ response because it placed NMN and NR in the same protocol, but it was still short and small.
Choose between actual products, not ingredients in the abstract
- Set the evidence goal: if your goal is a proven clinical outcome, neither precursor has a general win. If your goal is the better-documented label, compare the bottles.
- Normalize the dose: record milligrams per capsule, capsules per serving, servings per bottle, and cost per labeled serving.
- Check the public record: a matching finished-product lot result is stronger product evidence than a testing badge or raw-material purity result.
- Separate added ingredients: a combination formula creates another variable. Do not credit the precursor for evidence that belongs to a different ingredient.
- Read conflicts: several precursor trials involve manufacturers or industry-employed authors. That does not erase the results, but it belongs beside them.
For NMN bottles, our product specs database compares serving, price, formula, and public documentation in one table. The purity guide explains why a raw-material percentage and finished-capsule potency answer different questions.
If the ingredient decision is NMN, the five-product NMN comparison applies those fields to single-ingredient, liposomal, lower-dose, and combination formulas.
What the current evidence does not settle
- Long-term outcomes: a 14-day NAD+ comparison cannot establish years of safety or benefit.
- Lower retail doses: the direct study used 1,000 mg/day of each precursor, not every dose sold in stores.
- Brand superiority: the study does not rank the wider retail market.
- Clinical equivalence: comparable blood NAD+ changes do not prove equal effects on every tissue or health outcome.
- Individual response: group averages do not predict one person's response.
Sources
- Christen et al., direct comparison of NR, NMN, and nicotinamide, Nature Metabolism, 2026. Authors included Nestlé Research and Nestlé Health Science affiliations.
- Okabe et al., 250 mg/day NMN for 12 weeks, 2022.
- Yi et al., 300–900 mg/day NMN for 60 days, 2023.
- Martens et al., NR in healthy middle-aged and older adults, 2018.
- Conze et al., NR dose-ranging trial, 2019.